• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Monogram Technologies Reports Third Quarter 2024 Financial Results

    11/14/24 4:05:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email

    Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones

    Management to Host Business Update Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

    AUSTIN, TX / ACCESSWIRE / November 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the third quarter ended September 30, 2024.

    Third Quarter 2024 and Subsequent Operational Highlights

    • Closed an upsized and oversubscribed $13 million public offering

    • Submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's semi-active version of the mBôs TKA System and passed the FDA Administrative Review.

    • Received an Additional Information Request ("AIR") from the U.S. Food and Drug Administration ("FDA") regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application").

    • Secured initial strategic collaboration with Shalby Limited ("Shalby"), a global multi-specialty hospital chain and one of India's leading orthopedic hospital groups, to conduct a multicenter clinical trial to demonstrate the safety and effectiveness of the mBȏs TKA System.

    • Named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.

    Management Commentary

    "The third quarter was highlighted by an upsized and oversubscribed $13 million public offering and continued progress toward clearance for the semi-active version of the mBôs™ TKA System with the FDA," said Ben Sexson, Chief Executive Officer of Monogram. "Funds from the offering are expected to provide the cash runway to meet near-term commercialization milestones and resources to support key initiatives, including clinical trials and further development of our technology.

    "We are also working to obtain FDA clearance for our 510(k) submission. The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. On September 30, 2024, we received an Additional Information Request ("AIR") from the FDA regarding the submission, placing the application on hold pending a complete response to the AIR within 180 days. According to the 2nd Quarter FY2023 MDUFA V Performance Report, the FDA requested AIR on the first FDA review cycle for approximately 68% of 510(k) applications submitted in FY2022, and given our submission was over 28,000 pages, the AIR aligned with our expectations.

    "On October 16, 2024, we held a teleconference with the agency to address clarification questions, which we found constructive. We believe this response provides more transparency for our path forward. The FDA recommended an issue-specific submission (q submission) to discuss our planned approach for responding to the AIR. We anticipate holding the issue-specific meeting with the FDA by December 2024. If the FDA accepts the current planned approach, we believe we could address the AIR within the allotted period; however, this timeline could change based on the outcome of the December issue-specific meeting wherein the FDA may comment on the planned approach.

    "As we work to respond to the AIR, we have submitted an application to run an Outside the United States ("OUS") clinical trial on the fully autonomous version of the system in collaboration with Shalby Limited, a global multi-specialty hospital chain and one of India's leading orthopedic hospital groups. This would prepare the groundwork for the international launch of the mBȏs TKA System. Under the collaboration, Shalby will enroll patients at various sites in India for surgeons to evaluate the safety and effectiveness of the mBȏs TKA System with the Consensus CKS implant, which is substantially equivalent to the Monogram mPress implants for regulatory purposes.

    "During the quarter, we continued to hold cadaveric system demos, receiving surgeon and market interest for our hands-free, fully active system. With this support, we continue to believe in our thesis for orthopedic robotics and the value proposition of our proposed active robotic system and are confident such a system could be a game-changing advancement for the industry. Validating this thesis, we were recently named ‘Orthopedic Joint Replacement Company of the Year 2024' by Medical Tech Outlook from an expert panel of C-level executives, industry thought leaders, and the editorial board.

    "Looking ahead, we are highly focused on the response to the AIR and trying to obtain FDA clearance of our 510(k) submission as quickly and economically as possible. We are working with regulators, our Contract Research Organization (CRO) and the team at Shalby to obtain clearance and plan logistics for our anticipated multicenter clinical trial. We are also exploring further domestic and international relationships as we move toward commercialization. We look forward to additional updates in the weeks and months to come as we execute on our upcoming milestones," concluded Sexson.

    Upcoming Milestones

    • Issue-specific meeting with the FDA by December 2024.

    • Obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals.

    • Conduct OUS live-patient surgery trials and submit clinical trial data to FDA, with clinical trials expected to include 92 total knee replacement procedures with a 3-month clinical follow-up.

    • Seek to obtain clearance for the mBôs™ TKA System.

    • Continue exploring domestic relationships.

    • Continue expanding international relationships (the Company will be exhibiting at Arab Health in January 2025).

    Third Quarter 2024 Financial Results

    Research and development expenses for the third quarter ended September 30, 2024, were $2.2 million, compared to $2.7 million in the prior-year quarter. The R&D decrease was primarily a result of the Company finalizing the validation phase of the verification and validation phase of its robot prototype with the submission of the application for 510 (k) FDA clearance.

    Marketing and advertising expenses for the third quarter ended September 30, 2024, were $1.8 million, compared to $32,220 in the prior-year quarter. The increase in marketing and advertising expenses was driven by the marketing campaign to support the Series D preferred Stock Offering which commenced in July 2024 and closed on October 2, 2024.

    General & administrative expenses for the third quarter ended September 30, 2024, were $1.1 million compared to $1.1 million in the prior-year quarter.

    Net loss of $5.0 million for the third quarter ended September 30, 2024, as compared to a net loss of $1.0 million for the prior-year quarter. The increased loss variance was driven primarily by the increase in marketing expenses in the third quarter ended September 30, 2024 noted above combined with a noncash gain in the third quarter ended September 30, 2023, related to the change in fair market value of a warrant liability that is no longer outstanding.

    Cash and cash equivalents totaled $16.6 million as of September 30, 2024, compared to $13.6 million as of December 31, 2023. The company continues to marshal its resources with a focus on commercializing the mBôs™ TKA System as capital efficiently as possible.

    Third Quarter 2024 Business Update Conference Call

    Monogram Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will host the conference call, followed by a question-and-answer period.

    To access the call, please use the following information:

    Date:

    Tuesday, November 19, 2024

    Time:

    4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

    Toll-free dial-in number:

    1-877-407-9208

    International dial-in number:

    1-201-493-6784

    Conference ID:

    13749601

    The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1693340&tp_key=7ecb89475b and via the investor relations section of the Company's website here.

    About Monogram Technologies Inc.

    Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

    Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

    Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

    The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

    To learn more, visit www.monogramtechnologies.com.

    Forward-Looking Statements

    This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. For example, the Company's statement regarding the Company's proposed use of net proceeds is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

    Investor Relations

    Chris Tyson
    Executive Vice President
    MZ North America
    Direct: 949-491-8235
    [email protected]

    MONOGRAM ORTHOPAEDICS INC.
    CONDENSED BALANCE SHEETS

    September 30,

    December 31,

    2024

    2023

    (unaudited)

    Assets

    Current assets:

    Cash and cash equivalents

    $

    16,565,142

    $

    13,589,028

    Account receivable

    -

    364,999

    Prepaid expenses and other current assets

    2,065,863

    664,262

    Total current assets

    18,631,005

    14,618,289

    Equipment, net of accumulated depreciation

    829,216

    945,020

    Intangible assets, net

    391,250

    548,750

    Operating lease right-of-use assets

    370,795

    466,949

    Total assets

    $

    20,222,266

    $

    16,579,008

    Liabilities and Stockholders' Equity

    Current liabilities:

    Accounts payable

    $

    1,536,663

    $

    2,462,268

    Accrued liabilities

    874,797

    227,684

    Operating lease liabilities, current

    135,757

    128,266

    Total current liabilities

    2,547,217

    2,818,218

    Operating lease liabilities, non-current

    260,904

    363,724

    Total liabilities

    2,808,121

    3,181,942

    Commitments and contingencies

    -

    -

    Stockholders' equity:

    Series D Preferred Stock, par value $0.0001 per share; 6,000,000 shares authorized; 4,614,453 shares issued and outstanding

    4,614

    -

    Common stock, $.001 par value; 90,000,000 shares authorized; 34,312,261 and 31,338,391shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

    34,312

    31,338

    Additional paid-in capital

    81,083,405

    64,874,392

    Accumulated deficit

    (63,708,186

    )

    (51,508,664

    )

    Total stockholders' equity

    17,414,145

    13,397,066

    Total liabilities and stockholders' equity

    $

    20,222,266

    $

    16,579,008

    MONOGRAM ORTHOPAEDICS INC.
    CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

    Three months ended

    Nine months ended

    September 30,

    September 30,

    2024

    2023

    2024

    2023

    Product revenue

    $

    -

    $

    -

    -

    -

    Cost of goods sold

    -

    -

    $

    -

    $

    -

    Gross profit

    -

    -

    -

    -

    Operating expenses:

    Research and development

    2,214,729

    2,664,542

    7,047,112

    7,577,907

    Marketing and advertising

    1,838,937

    32,220

    2,050,347

    2,844,748

    General and administrative

    1,093,456

    1,060,270

    3,293,344

    2,968,644

    Total operating expenses

    5,147,122

    3,757,032

    12,390,803

    13,391,299

    Loss from operations

    (5,147,122

    )

    (3,757,032

    )

    (12,390,803

    )

    (13,391,299

    )

    Other income:

    Change in fair value of warrant liability

    -

    2,646,399

    -

    3,088,533

    Interest income and other, net

    112,621

    114,973

    312,142

    211,843

    Total other income

    112,621

    2,761,372

    312,142

    3,300,376

    Net loss before taxes

    (5,034,501

    )

    (995,660

    )

    (12,078,661

    )

    (10,090,923

    )

    Income taxes

    -

    -

    -

    -

    Net loss

    $

    (5,034,501

    )

    $

    (995,660

    )

    $

    (12,078,661

    )

    $

    (10,090,923

    )

    Basic and diluted loss per common share

    $

    (0.16

    )

    $

    (0.03

    )

    $

    (0.38

    )

    $

    (0.52

    )

    Weighted-average number of basic and diluted shares outstanding

    32,223,656

    29,284,949

    31,806,252

    19,482,606

    MONOGRAM ORTHOPAEDICS INC.
    CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

    Nine months ended

    September 30,

    2024

    2023

    Operating activities:

    Net loss

    $

    (12,078,661

    )

    $

    (10,090,923

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Stock-based compensation

    942,528

    1,158,499

    Other expenses settled with stock issuances

    50,000

    80,000

    Loss from change in fair value of common stock make-whole obligation

    35,749

    -

    Depreciation and amortization

    321,114

    307,293

    Change in fair value of warrant liability

    -

    (3,088,533

    )

    Changes in non-cash working capital balances:

    Account receivable

    364,999

    -

    Other current assets

    (168,691

    )

    273,079

    Accounts payable

    (925,605

    )

    1,121,822

    Accrued liabilities

    490,504

    (197,243

    )

    Operating lease assets and liabilities, net

    825

    5,622

    Cash used in operating activities

    (10,967,238

    )

    (10,430,384

    )

    Investing activities:

    Purchases of equipment

    (47,809

    )

    (40,765

    )

    Cash used in investing activities

    (47,809

    )

    (40,765

    )

    Financing activities:

    Proceeds from issuances of Common Stock, net of cash costs

    4,177,931

    15,254,300

    ELOC issuance cost

    -

    (523,362

    )

    Proceeds from issuances of Series C Preferred Stock, net

    -

    147,042

    Proceeds from issuances of Series D Preferred Stock, net

    9,813,230

    -

    Cash provided by financing activities

    13,991,161

    14,877,980

    Increase (decrease) in cash and cash equivalents during the period

    2,976,114

    4,406,831

    Cash and cash equivalents, beginning of the period

    13,589,028

    10,468,645

    Cash and cash equivalents, end of the period

    $

    16,565,142

    $

    14,875,476

    Noncash investing and financing activities:

    Receivable from stock offerings' selling agent

    $

    1,378,867

    $

    -

    Amortization of deferred issuance costs of Common Stock Purchase Agreement

    $

    145,956

    $

    -

    Series D Preferred Stock dividends payable

    $

    120,860

    $

    -

    Cashless exercise of warrant

    $

    246

    $

    926,335

    Common Stock issued for services related to Common Stock Purchase Agreement

    $

    -

    $

    247,980

    SOURCE: Monogram Technologies Inc.



    View the original press release on accesswire.com

    Get the next $MGRM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monogram Technologies Reports First Quarter 2025 Financial Results

      Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

      5/14/25 4:01:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

      Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data RequestManagement Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TEXAS / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application").The Application was submitted on

      12/18/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

      AUSTIN, TEXAS / ACCESSWIRE / December 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events."Our senior management team has purchased shares in the open market, reflecting high confidence in our strategy and expectation to create long-term shareholder value," said Ben Sexson

      12/2/24 4:05:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Knape Noel was granted 288,461 shares (SEC Form 4)

      4 - Monogram Technologies Inc. (0001769759) (Issuer)

      11/26/24 8:52:37 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Knape Noel

      4 - MONOGRAM ORTHOPAEDICS INC (0001769759) (Issuer)

      4/26/24 3:28:17 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Monogram Technologies with a new price target

      ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

      12/9/24 7:59:36 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Monogram Accepted to NVIDIA Inception Program

      Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

      4/11/24 1:20:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Monogram Technologies Inc.

      10-Q - Monogram Technologies Inc. (0001769759) (Filer)

      5/14/25 3:59:51 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Monogram Technologies Inc. (0001769759) (Filer)

      4/29/25 6:05:28 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Monogram Technologies Inc.

      S-8 - Monogram Technologies Inc. (0001769759) (Filer)

      4/17/25 3:12:04 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Financials

    Live finance-specific insights

    See more
    • Monogram Technologies Reports First Quarter 2025 Financial Results

      Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

      5/14/25 4:01:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

      AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

      11/12/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Announces Preferred Stock Dividends

      AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024. Holders of record will receive the dividend

      10/1/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care